Receptor-targeted nanocarriers for therapeutic delivery to cancer

Area of Science:

• Nanomedicine
• Drug Delivery Systems
• Oncology

Background:

• Efficient and site-specific delivery of cancer therapeutics remains a significant clinical challenge.
• Nanocarriers like liposomes and nanoparticles enhance drug bioavailability and pharmacokinetics, partly via the enhanced permeability and retention (EPR) effect.
• Targeting ligands conjugated to nanocarriers enable selective delivery to tumor cells or vasculature, improving therapeutic outcomes.

Purpose of the Study:

• To review recent advancements in the development of targeted nanocarriers for cancer therapy.
• To introduce novel concepts including multi-targeting and multi-functional nanoparticles.
• To highlight strategies for improving drug bioavailability and achieving site-specific delivery.

Main Methods:

• Review of literature on targeted nanocarrier development.
• Analysis of various targeting ligands (e.g., folate, antibodies, aptamers).
• Discussion of nanoparticle functionalities for imaging and triggered release.

Main Results:

• Targeted nanocarrier delivery has demonstrated improved therapeutic responses in vitro and in vivo.
• Various ligands have been successfully employed for receptor-targeted delivery.
• Nanoparticles can be engineered with multiple functionalities for enhanced therapeutic strategies.

Conclusions:

• Targeted nanocarriers represent a promising approach for improving cancer treatment efficacy.
• Multi-targeting and multi-functional nanoparticles offer novel avenues for advanced cancer therapy.
• Further development in nanocarrier design is crucial for overcoming drug delivery challenges in oncology.